High NRF2 Levels Correlate with Poor Prognosis in Colorectal Cancer Patients and with Sensitivity to the Kinase Inhibitor AT9283 In Vitro

• Main Authors: Laura Torrente, Gunjit Maan, Asma Oumkaltoum Rezig, Jean Quinn, Angus Jackson, Andrea Grilli, Laura Casares, Ying Zhang, Evgeny Kulesskiy, Jani Saarela, Silvio Bicciato, Joanne Edwards, Albena T. Dinkova-Kostova, Laureano de la Vega
• Format: Article
• Language: English
• Published: MDPI AG 2020-09-01
• Series: Biomolecules
• Subjects: NRF2; colorectal cancer; drug screening
• Online Access: https://www.mdpi.com/2218-273X/10/10/1365

Aberrant hyperactivation of nuclear factor erythroid 2 (NF-E2) p45-related factor 2 (NRF2) is a common event in many tumour types and associates with resistance to therapy and poor patient prognosis; however, its relevance in colorectal tumours is not well-established. Measuring the expression of surrogate genes for NRF2 activity in silico, in combination with validation in patients’ samples, we show that the NRF2 pathway is upregulated in colorectal tumours and that high levels of nuclear NRF2 correlate with a poor patient prognosis. These results highlight the need to overcome the protection provided by NRF2 and present an opportunity to selectively kill cancer cells with hyperactive NRF2. Exploiting the CRISPR/Cas9 technology, we generated colorectal cancer cell lines with hyperactive NRF2 and used them to perform a drug screen. We identified AT9283, an Aurora kinase inhibitor, for its selectivity towards killing cancer cells with hyperactive NRF2 as a consequence to either genetic or pharmacological activation. Our results show that hyperactivation of NRF2 in colorectal cancer cells might present a vulnerability that could potentially be therapeutically exploited by using the Aurora kinase inhibitor AT9283.